Literature DB >> 12516986

Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section.

N J Cooper1, A J Sutton, K R Abrams.   

Abstract

Economic evaluation of health care interventions based on decision analytic modelling can generate valuable information for health policy decision makers. However, the usefulness of the results obtained depends on the quality of the data input into the model; that is, the accuracy of the estimates for the costs, effectiveness, and transition probabilities between the different health states of the model. The aim of this paper is to review the use of Bayesian decision models in economic evaluation and to demonstrate how the individual components required for decision analytical modelling (i.e., systematic review incorporating meta-analyses, estimation of transition probabilities, evaluation of the model, and sensitivity analysis) may be addressed simultaneously in one coherent Bayesian model evaluated using Markov Chain Monte Carlo simulation implemented in the specialist Bayesian statistics software WinBUGS. To illustrate the method described, a simple probabilistic decision model is developed to evaluate the cost implications of using prophylactic antibiotics in caesarean section to reduce the incidence of wound infection. The advantages of using the Bayesian statistical approach outlined compared to the conventional classical approaches to decision analysis include the ability to: (i) perform all necessary analyses, including all intermediate analyses (e.g., meta-analyses) required to derive model parameters, in a single coherent model; (ii) incorporate expert opinion either directly or regarding the relative credibility of different data sources; (iii) use the actual posterior distributions for parameters of interest (opposed to making distributional assumptions necessary for the classical formulation); and (iv) incorporate uncertainty for all model parameters.

Entities:  

Mesh:

Year:  2002        PMID: 12516986     DOI: 10.1191/0962280202sm306ra

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  15 in total

1.  Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.

Authors:  Mark J C Nuijten
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Incorporating quality of evidence into decision analytic modeling.

Authors:  R Scott Braithwaite; Mark S Roberts; Amy C Justice
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

Review 3.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.

Authors:  Jeroen P Jansen; Sabine Gaugris; Ernest H Choy; Andrew Ostor; Julian T Nash; Wiro Stam
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics.

Authors:  Kimbach Tran Carpiuc; Gianantonio Rosti; Fausto Castagnetti; Maarten Treur; Jennifer Stephens
Journal:  Onco Targets Ther       Date:  2010-10-11       Impact factor: 4.147

6.  Subgroups and heterogeneity in cost-effectiveness analysis.

Authors:  Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.

Authors:  Jeroen P Jansen; Stephanie D Taylor
Journal:  Int J Rheumatol       Date:  2011-06-24

Review 8.  Bayesian methods for evidence synthesis in cost-effectiveness analysis.

Authors:  A E Ades; Mark Sculpher; Alex Sutton; Keith Abrams; Nicola Cooper; Nicky Welton; Guobing Lu
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.

Authors:  Panagiotis Petrou; Michael A Talias
Journal:  Cost Eff Resour Alloc       Date:  2014-05-03

10.  WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: a NICE Medical Technology Guidance.

Authors:  Iain Willits; Kim Keltie; Joyce Craig; Andrew Sims
Journal:  Appl Health Econ Health Policy       Date:  2014-06       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.